DOCSLIB.ORG

Burnstock G. a Basis for Distinguishing Two Types of Purinergic Receptor

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Burnstock G. a Basis for Distinguishing Two Types of Purinergic Receptor CC/NUMBER 40 This Week’s Citation Classic ~ OCTOBER 1, 1990 Burnstock G. A basis for distinguishing two types of purinergic receptor. (Straub R W & Sods L. eds.) Ce/I membrane receptors for drugs andItormones: a multidisciplinary approach. New York: Raven Press. 1978. p. 107-18. [Department of Anatomy and Embryology, University College London. England] This paperwas the tirst to distinguish two major subclass- after I proposed this division of purinoceptors, a es of receptor for extracellular purine nucleosides and cartoon appeared in my laboratory (see below), I nucleotides. Thesesubstances were known to have potent suspect drawn by Ian Mackenzie, showing healthy actions since the seminal studies of Drury and Szent- scepticism for my new hypothesis, and another was GyOrgyi in t929.t The subclassification into P~-and p, sent by my old colleague David Satchell from Mel- purinoceptors was based on the relative potency of ATP, bourne. ADP, AMP, and adenosine; the effectiveness of methyl- Nevertheless, in the years that followed, this das- xanthines as antagonists: and mediation or not by adenyl- sification was accepted by most laboratories, and ate cyclase. This recognition of distinct receptors for subdivisions of both P - and Pa-purinoceptors have adenosine and AlP was a trigger ior considerable expan- now been proposed; Ai1 and A subclasses of the Pi- sion of the field and resolved many of the earlier am- 2 purinoceptors~4and Pzx and P2y subclasses of the biguities. The Sd® indicates that this chapter has been Prpurinoceptor No less than 10 books have been cited in over 400 publications.1 published on purinoceptors in recent years (for ex- —~ ample, references 5 and 6). Several meetings and Purinergic Receptors—Subclassification symposia have been devoted to this subject, and I was invited to deliver the Ariëns Lecture on and Physiological Roles 4. “Purinergic Receptors” in 1987 in Gent and was Geoffrey Burnstock given an award for my contribution to “The Con- Department of Anatomy and cept of Purinergic Transmission” at the meeting Developmental Biology and held in Bethesda, Maryland, September 1989, on Centre for Neuroscience “Purine Nucleosides and Nucleotides in Cell Sig- University College London nalling: Targets for New Drugs” I was also asked to London WC1 E6BT present the opening overview at a meeting held in England Philadelphia, November 1989, on “Biological Ac- June 5, 1990 tions of Extracellular ATP/’ sponsored by the New York Academy of Sciences, and at the 4th Interna- Purinergic receptors were implicit in the puriner- tional. Symposium on Adenosine and Adenine gic hypothesis that I proposed in 1972,2 which sug- Nucleotides held at Lake Yamanaka, Japan, May gested that nonadrenergic, noncholinergic (termed 13-17, 1990. “purinergic”) nerves supplying the smooth muscle Currently particular interest is being shown by of the gut and bladder utilise a purine nucleotide as both dinicians and the drug industry in the the principal neurotransmitter. Thus I was asked by therapeutic potential of purinoceptor agonists and my old friends Ralph Straub and Liliana Boils to antagonists, especially for cardiovascular diseases, present a paper on “purinergic receptors” at the for abnormalities in urinary and respiratory sys- meeting they were organising in Crans-sur-Sierre, tems, and in behavioural disorders. Switzerland, june 1977, which was entitled “Drugs, Hormones and Membranes.” This was a trigger for me to make a thorough analysis of the literature on the actions ofadenyl compounds on a wide range of tissues. I remember running into my laboratory at PURINAL University College London, trailing a huge, elon- gated table to declare to my group that I had spotted a pattern to the actions of adenyl com- pounds and believed that there was a clear distinc- tion between receptors for adenosine and AMP or the one hand and ATP/ADP on the other. Some 0 the hints for this subdivision came from experi- ments on smooth muscle in our own laboratory, such as the distinct separation of ATP/ADP from AMP/adenosine in the dose-response curves of in- testinal smooth muscle and the opposite excitatory or inhibitory actions of ATP and adenosine, respec- tively, in the bladder. There were also reports of the differential effects of these purines in other tissues, such as brain, pancreas, liver, and blood cells. Soon I. Drury A N & Szeni.G~orgyiA. The physiological activity of adenine cotnpounds with especial reference to their action upon the mammalian hcart. I. Phvsiol.—London 68:213-37. 929. (Cited 485 times since 945.) 2. Burnsiock G. Purinergic nerves. Pharmucol. Re”. 24:509-81, 972. (Cited 1.135 times.) ISee also: Burnstock G. Citation Classic. Current Contents/Life Sciences 28(3):ts. 21 January 985.1 3. Ribeiro J A. Adenosine receptors in the nervous system. London: Taylor & Francis, 1989, 4. Burostock G & Kennedy C. Is there a basis for disttnguishing two types of purinoccptor? Ceo Pharmacol 16:433-40. 985. ICited ISO tinres.l 5. Burnstock 6, ed. Purinergtc receptorn. London: Chupman & Halt. 1981. 365 p. 6. Jacobson K, DalyJ & %langaniello V. eds. Purines ‘n cellular signalling: targets/or new drugs. New York: Springer-verlag. 1990, 18 ©1990 by SI® CURRENT CONTENTS ® ,~ -r.
Load more

Recommended publications
  • Introduction: P2 Receptors
    Current Topics in Medicinal Chemistry 2004, 4, 793-803 793 Introduction: P2 Receptors Geoffrey Burnstock* Autonomic Neuroscience Institute, Royal Free and University College, London NW3 2PF, U.K. Abstract: The current status of ligand gated ion channel P2X and G protein-coupled P2Y receptor subtypes is described. This is followed by a summary of what is known of the distribution and roles of these receptor subtypes. Potential therapeutic targets of purinoceptors are considered, including those involved in cardiovascular, nervous, respiratory, urinogenital, gastrointestinal, musculo-skeletal and special sensory diseases, as well as inflammation, cancer and diabetes. Lastly, there are some speculations about future developments in the purinergic signalling field. HISTORICAL BACKGROUND It is widely recognised that purinergic signalling is a primitive system [19] involved in many non-neuronal as well The first paper describing the potent actions of adenine as neuronal mechanisms and in both short-term and long- compounds was published by Drury & Szent-Györgyi in term (trophic) events [20], including exocrine and endocrine 1929 [1]. Many years later, ATP was proposed as the secretion, immune responses, inflammation, pain, platelet transmitter responsible for non-adrenergic, non-cholinergic aggregation, endothelial-mediated vasodilatation, cell proli- transmission in the gut and bladder and the term ‘purinergic’ feration and death [8, 21-23]. introduced by Burnstock [2]. Early resistance to this concept appeared to stem from the fact that ATP was recognized first P2X Receptors for its important intracellular roles and the intuitive feeling was that such a ubiquitous and simple compound was Members of the existing family of ionotropic P2X1-7 unlikely to be utilized as an extracellular messenger.
    [Show full text]
  • Regulation of Microglial Functions by Purinergic Mechanisms in the Healthy and Diseased CNS
    cells Review Regulation of Microglial Functions by Purinergic Mechanisms in the Healthy and Diseased CNS Peter Illes 1,2,*, Patrizia Rubini 2, Henning Ulrich 3, Yafei Zhao 4 and Yong Tang 2,4 1 Rudolf Boehm Institute for Pharmacology and Toxicology, University of Leipzig, 04107 Leipzig, Germany 2 International Collaborative Centre on Big Science Plan for Purine Signalling, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China; [email protected] (P.R.); [email protected] (Y.T.) 3 Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo 748, Brazil; [email protected] 4 Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China; [email protected] * Correspondence: [email protected]; Tel.: +49-34-1972-46-14 Received: 17 March 2020; Accepted: 27 April 2020; Published: 29 April 2020 Abstract: Microglial cells, the resident macrophages of the central nervous system (CNS), exist in a process-bearing, ramified/surveying phenotype under resting conditions. Upon activation by cell-damaging factors, they get transformed into an amoeboid phenotype releasing various cell products including pro-inflammatory cytokines, chemokines, proteases, reactive oxygen/nitrogen species, and the excytotoxic ATP and glutamate. In addition, they engulf pathogenic bacteria or cell debris and phagocytose them. However, already resting/surveying microglia have a number of important physiological functions in the CNS; for example, they shield small disruptions of the blood–brain barrier by their processes, dynamically interact with synaptic structures, and clear surplus synapses during development. In neurodegenerative illnesses, they aggravate the original disease by a microglia-based compulsory neuroinflammatory reaction.
    [Show full text]
  • Purinergic Receptors Brian F
    Chapter 21 Purinergic receptors Brian F. King and Geoffrey Burnstock 21.1 Introduction The term purinergic receptor (or purinoceptor) was first introduced to describe classes of membrane receptors that, when activated by either neurally released ATP (P2 purinoceptor) or its breakdown product adenosine (P1 purinoceptor), mediated relaxation of gut smooth muscle (Burnstock 1972, 1978). P2 purinoceptors were further divided into five broad phenotypes (P2X, P2Y, P2Z, P2U, and P2T) according to pharmacological profile and tissue distribution (Burnstock and Kennedy 1985; Gordon 1986; O’Connor et al. 1991; Dubyak 1991). Thereafter, they were reorganized into families of metabotropic ATP receptors (P2Y, P2U, and P2T) and ionotropic ATP receptors (P2X and P2Z) (Dubyak and El-Moatassim 1993), later redefined as extended P2Y and P2X families (Abbracchio and Burnstock 1994). In the early 1990s, cDNAs were isolated for three heptahelical proteins—called P2Y1, P2Y2, and P2Y3—with structural similarities to the rhodopsin GPCR template. At first, these three GPCRs were believed to correspond to the P2Y, P2U, and P2T receptors. However, the com- plexity of the P2Y receptor family was underestimated. At least 15, possibly 16, heptahelical proteins have been associated with the P2Y receptor family (King et al. 2001, see Table 21.1). Multiple expression of P2Y receptors is considered the norm in all tissues (Ralevic and Burnstock 1998) and mixtures of P2 purinoceptors have been reported in central neurones (Chessell et al. 1997) and glia (King et al. 1996). The situation is compounded by P2Y protein dimerization to generate receptor assemblies with subtly distinct pharmacological proper- ties from their constituent components (Filippov et al.
    [Show full text]
  • Glutamatergic and Purinergic Receptor-Mediated Calcium Transients in Bergmann Glial Cells
    The Journal of Neuroscience, April 11, 2007 • 27(15):4027–4035 • 4027 Cellular/Molecular Glutamatergic and Purinergic Receptor-Mediated Calcium Transients in Bergmann Glial Cells Richard Piet and Craig E. Jahr Vollum Institute, Oregon Health & Science University, Portland, Oregon 97239 2ϩ Astrocytesrespondtoneuronalactivitywith[Ca ]i increasesafteractivationofspecificreceptors.Bergmannglialcells(BGs),astrocytes of the cerebellar molecular layer (ML), express various receptors that can mobilize internal Ca 2ϩ. BGs also express Ca 2ϩ permeable AMPA receptors that may be important for maintaining the extensive coverage of Purkinje cell (PC) excitatory synapses by BG processes. Here, we examined Ca 2ϩ signals in single BGs evoked by synaptic activity in cerebellar slices. Short bursts of high-frequency stimulation of the ML elicited Ca 2ϩ transients composed of a small-amplitude fast rising phase, followed by a larger and slower rising phase. The first phase resulted from Ca 2ϩ influx through AMPA receptors, whereas the second phase required release of Ca 2ϩ from internal stores initiated by P2 purinergic receptor activation. We found that such Ca 2ϩ responses could be evoked by direct activation of neurons releasing ATP onto BGs or after activation of metabotropic glutamate receptor 1 on these neurons. Moreover, examination of BG and PC responses to various synaptic stimulation protocols suggested that ML interneurons are likely the cellular source of ATP. Key words: cerebellum; neuron–glia interaction; ATP; AMPA receptors; mGluR1; synaptic
    [Show full text]
  • P2X and P2Y Receptors
    Tocris Scientific Review Series Tocri-lu-2945 P2X and P2Y Receptors Kenneth A. Jacobson Subtypes and Structures of P2 Receptor Molecular Recognition Section, Laboratory of Bioorganic Families Chemistry, National Institute of Diabetes and Digestive and The P2 receptors for extracellular nucleotides are widely Kidney Diseases, National Institutes of Health, Bethesda, distributed in the body and participate in regulation of nearly Maryland 20892, USA. E-mail: [email protected] every physiological process.1,2 Of particular interest are nucleotide Kenneth Jacobson serves as Chief of the Laboratory of Bioorganic receptors in the immune, inflammatory, cardiovascular, muscular, Chemistry and the Molecular Recognition Section at the National and central and peripheral nervous systems. The ubiquitous Institute of Diabetes and Digestive and Kidney Diseases, National signaling properties of extracellular nucleotides acting at two Institutes of Health in Bethesda, Maryland, USA. Dr. Jacobson is distinct families of P2 receptors – fast P2X ion channels and P2Y a medicinal chemist with interests in the structure and receptors (G-protein-coupled receptors) – are now well pharmacology of G-protein-coupled receptors, in particular recognized. These extracellular nucleotides are produced in receptors for adenosine and for purine and pyrimidine response to tissue stress and cell damage and in the processes nucleotides. of neurotransmitter release and channel formation. Their concentrations can vary dramatically depending on circumstances. Thus, the state of activation of these receptors can be highly dependent on the stress conditions or disease states affecting a given organ. The P2 receptors respond to various extracellular mono- and dinucleotides (Table 1). The P2X receptors are more structurally restrictive than P2Y receptors in agonist selectivity.
    [Show full text]
  • XL P2RY8 Del Order No.: Deletion Probe D-5150-100-OG
    XL P2RY8 del Order No.: Deletion Probe D-5150-100-OG Description XL P2RY8 del detects deletions in the short arm of chromosome X and Y at Xp22.33 and Yp11.32, respectively. The orange labeled probe spans P2RY8 and extends distally, the green labeled probe covers the 5´end of P2RY8 and extends proximally. Clinical Details Acute lymphoblastic leukemia (ALL) is the most common malignancy in children (prevalence of approximately 1:1500). Children with Down syndrome have a 10- to 20- fold increased risk of developing acute leukemia. B-Cell dependent BCR-ABL1-like ALL, also known as Philadelphia chromosome (Ph)-like ALL, is a high-risk subset with a gene expression profile that shares significant overlap with that of Ph-positive (Ph+) ALL, but lacking the BCR-ABL1 fusion. In 2017, the WHO recognized BCR-ABL1-like ALL as new entity. Chromosomal rearrangements resulting in the overexpression of cytokine receptor like factor 2 (CRLF2) can be found in up to 50% of BCR-ABL1-like ALL cases. The CRLF2 gene is located in the pseudoautosomal region 1 (PAR1) of the X and the Y XL P2RY8 del hybridized to bone marrow cells. One chromosome. CRLF2 rearrangements result in increased protein levels, which initiate aberrant cell of a patient with a gonosomal significantly enhanced JAK/STAT signaling, whereby disproportionate JAK and constellation of XXY is shown. The two orange-green subsequent STAT5 activation induces strongly enhanced B-cell activation and fusion signals represent the two unaffected CRLF2- proliferation. One of the genetic mechanisms leading to constitutive overexpression P2RY8 loci.
    [Show full text]
  • Antidepressant-Like Effects of P2 Purinergic Antagonist PPADS Is Dependent on Serotonergic and Noradrenergic Integrity
    bioRxiv preprint doi: https://doi.org/10.1101/086983; this version posted November 10, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Title: Antidepressant-like effects of P2 purinergic antagonist PPADS is dependent on serotonergic and noradrenergic integrity. Authors: Cassiano R. A. F. Diniza, Murilo Rodriguesb, Plínio C. Casarottoc, Vítor S. Pereirad, Carlos C. Crestanie, Sâmia R.L. Jocab,d*. aSchool of Medicine, Campus USP, Ribeirão Preto, SP 14049-900, Brazil bDepartment of Physics and Chemistry, School of Pharmaceutical Sciences, Campus USP, Ribeirão Preto, SP 14040-904, Brazil. cNeuroscience Center, University of Helsinki, Finland dDepartment of Clinical Medicine - Translational Neuropsychiatry Unit, Aarhus University, Denmark eLaboratory of Pharmacology, School of Pharmaceutical Sciences, UNESP - Universidade Estadual Paulista, Araraquara, SP, Brazil *Corresponding Author: Sâmia Joca. Department of Physics and Chemistry - School of Pharmaceutical Sciences of Ribeirão Preto (FCFRP) University of São Paulo (USP). AvCafe, s/n, 14040-903, Ribeirão Preto - SP, Brazil. Phone: +55-16-33154705 -Fax: +55-16-33154880. e-mail: [email protected] Samia R. L. Joca: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/086983; this version posted November 10, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.
    [Show full text]
  • The P2Y12 Receptor Regulates Microglial Activation by Extracellular Nucleotides
    ARTICLES The P2Y12 receptor regulates microglial activation by extracellular nucleotides Sharon E Haynes1, Gunther Hollopeter1,4, Guang Yang2, Dana Kurpius3, Michael E Dailey3, Wen-Biao Gan2 & David Julius1 Microglia are primary immune sentinels of the CNS. Following injury, these cells migrate or extend processes toward sites of tissue damage. CNS injury is accompanied by release of nucleotides, serving as signals for microglial activation or chemotaxis. Microglia express several purinoceptors, including a Gi-coupled subtype that has been implicated in ATP- and ADP-mediated migration in vitro. Here we show that microglia from mice lacking Gi-coupled P2Y12 receptors exhibit normal baseline motility but are unable to polarize, migrate or extend processes toward nucleotides in vitro or in vivo. Microglia in P2ry12–/– mice show significantly diminished directional branch extension toward sites of cortical damage in the living mouse. Moreover, P2Y12 http://www.nature.com/natureneuroscience expression is robust in the ‘resting’ state, but dramatically reduced after microglial activation. These results imply that P2Y12 is a primary site at which nucleotides act to induce microglial chemotaxis at early stages of the response to local CNS injury. In the spinal cord and brain, microglia migrate or project cellular candidate for mediating morphological responses of microglia to processes toward sites of mechanical injury or tissue damage1–3,where extracellular nucleotides. 4,5 they clear debris and release neurotrophic or neurotoxic agents .As The P2Y12 receptor was initially identified on platelets, where it such, microglial activation, or lack thereof, has been proposed to regulates their conversion from the inactive to active state during the influence degenerative and regenerative processes in the brain and clotting process12,14,15.
    [Show full text]
  • Purinergic Signalling in the CNS Geoffrey Burnstock*
    24 The Open Neuroscience Journal, 2010, 4, 24-30 Open Access Purinergic Signalling in the CNS Geoffrey Burnstock* Autonomic Neuroscience Centre, University College Medical School, Rowland Hill Street, London NW3 2PF, UK Abstract: Purinergic neurotransmission, involving release of ATP as an efferent neurotransmitter was first proposed in 1972. Later it was recognised as a cotransmitter in peripheral nerves and more recently as a cotransmitter with glutamate, noradrenaline, GABA, acetylcholine and dopamine in the CNS. Both ion channel and G protein-coupled receptors for purines and pyrimidines are widely expressed in the brain and spinal cord. They mediate both fast signalling in neuro- transmission and neuromodulation and long-term (trophic) signalling in cell proliferation, differentiation and death. Purinergic signalling is prominent in neuron-glial cell interactions. Purinergic signalling has been implicated in learning and memory, locomotor activity and feeding behaviour. There is increasing interest in the involvement of purinergic sig- nalling in the pathophysiology of the CNS, including trauma, ischaemia, epilepsy, neurodegenerative diseases, neuropsy- chiatric and mood disorders. Keywords: ATP, adenosine, cotransmission, epilepsy, glia, memory, neurodegenerative diseases, purinoceptors, sleep. INTRODUCTION important being the P2U receptor, which could recognize pyrimidines such as uridine 5'-triphosphate (UTP) as well as The concept of purinergic neurotransmission was born in ATP [12]. Abbracchio and Burnstock [13], on the basis
    [Show full text]
  • LPAR6 Antibody (Center) Blocking Peptide Synthetic Peptide Catalog # Bp12707c
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 LPAR6 Antibody (Center) Blocking peptide Synthetic peptide Catalog # BP12707c Specification LPAR6 Antibody (Center) Blocking peptide LPAR6 Antibody (Center) Blocking peptide - - Background Product Information The protein encoded by this gene belongs to Primary Accession P43657 the family ofG-protein coupled receptors, that are preferentially activated byadenosine and uridine nucleotides. This gene aligns with LPAR6 Antibody (Center) Blocking peptide - Additional Information aninternal intron of the retinoblastoma susceptibility gene in thereverse orientation. Alternative splicing results in multipletranscript Gene ID 10161 variants. Other Names LPAR6 Antibody (Center) Blocking peptide Lysophosphatidic acid receptor 6, LPA - References receptor 6, LPA-6, Oleoyl-L-alpha-lysophosphatidic acid Pasternack, S.M., et al. Arch. Dermatol. Res. receptor, P2Y purinoceptor 5, P2Y5, 301(8):621-624(2009)Yanagida, K., et al. J. Purinergic receptor 5, RB intron encoded G-protein coupled receptor, LPAR6, P2RY5 Biol. Chem. 284(26):17731-17741(2009)Tariq, M., et al. Br. J. Dermatol. Format 160(5):1006-1010(2009)Shimomura, Y., et al. J. Peptides are lyophilized in a solid powder Invest. Dermatol. format. Peptides can be reconstituted in 129(3):622-628(2009)Dereure, O. Ann solution using the appropriate buffer as Dermatol Venereol 135(11):794-795(2008) needed. Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures. LPAR6 Antibody (Center) Blocking peptide - Protein Information Name LPAR6 Synonyms P2RY5 Function Binds to oleoyl-L-alpha-lysophosphatidic acid (LPA).
    [Show full text]
  • The Role of Purinergic P2X and P2Y Receptors in Hearing Loss
    netic ho s & P A f u o l d i a o n l r o g u y o Gonzalez, J phonet Audiol 2018, 4:1 J Journal of Phonetics & Audiology DOI: 10.4172/2471-9455.1000136 ISSN: 2471-9455 Mini Review Open Access The Role of Purinergic P2X and P2Y Receptors in Hearing Loss Gonzalez-Gonzalez S * CILcare, Parc Scientifique Agropolis, Montpellier, France *Corresponding Author: Dr Sergio Gonzalez-Gonzalez, CILcare, Parc Scientifique Agropolis, Montpellier, France, E-mail: [email protected] Received date: December 06 2017; Accepted date: December 30, 2017; Published date: January 10, 2018 Copyright: ©2017 Gonzalez SG. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Hearing loss is the most common form of sensorineural impairment, affecting 5.3% of the worldwide human population. Whereas 1 in 500 children is born with hearing disorders, sudden or progressive forms of hearing loss can appear at adult age. However, the physiological and molecular mechanisms involved in this pathological process remain unclear. Interestingly, an increasing number of studies have demonstrated that purinergic receptors could play a key role on hearing disorders and auditory pathway dysfunctions. This mini review summarizes the current data suggesting a key role of purinergic signaling in cochlear hair cell functions and their involvement in progressive hearing loss. Taken together, these studies provide new knowledge in the biochemical and physiological mechanism of purinergic receptors in cochlear cell functions and open the door for the development of new drugs candidates involved in hearing loss treatment.
    [Show full text]
  • A Focus on Microglia and P2X4R
    JPET Fast Forward. Published on February 29, 2020 as DOI: 10.1124/jpet.120.265017 This article has not been copyedited and formatted. The final version may differ from this version. JPET # 265017 Title: Sex-dependent mechanisms of chronic pain: A focus on microglia and P2X4R Authors and Affiliations: Katherine Halievski1, 2, Shahrzad Ghazisaedi1, 2, 3, Michael W. Salter1, 2, 3 1. Neurosciences and Mental Health Program, The Hospital for Sick Children, Toronto ON 2. The University of Toronto Centre for the Study of Pain, Toronto ON Downloaded from 3. The Department of Physiology, University of Toronto, Toronto ON jpet.aspetjournals.org at ASPET Journals on September 24, 2021 1 JPET Fast Forward. Published on February 29, 2020 as DOI: 10.1124/jpet.120.265017 This article has not been copyedited and formatted. The final version may differ from this version. JPET # 265017 Running title: Microglia-P2X4R sex differences in pain Corresponding author: Michael W. Salter The Hospital for Sick Children 686 Bay St. Toronto, ON M5G 0A4 Canada tel: (416) 813-6272 fax: (416) 813-7921 [email protected] Number of text pages: 15 Number of references: 72 Downloaded from Number of tables: 1 Number of words in the Abstract: 137 Number of words in the Body: 5013 jpet.aspetjournals.org Abbreviations: brain-derived neurotrophic factor (BDNF) chemokine (C-C motif) ligand (CCL) colony-stimulating factor 1 (CSF-1) interleukin-6 (IL-6) interferon regulatory factor (IRF) at ASPET Journals on September 24, 2021 lipopolysaccharide (LPS) N-methyl-D-aspartate receptor (NMDAR) periaqueductal gray (PAG) peripheral nerve injury (PNI) purinergic receptor, ionotropic (P2XR) prostaglandin E2 (PGE-2) vesicular nucleotide transporter (VNUT) Section assignment: Special Section: Sexual Dimorphism in Neuroimmune Cells 2 JPET Fast Forward.
    [Show full text]